Advances in imaging in differentiated thyroid cancer: focus on SPECT/CT and PET/CT

References

• King AD. Imaging for staging and management of thyroid cancer. Cancer Imaging8, 57–69 (2008).
   PubMedGoogle Scholar
• Caron NR, Clark OH. Well differentiated thyroid cancer. Scand. J. Surg.93(4), 261–271 (2004).
   PubMedGoogle Scholar
• Jonklaas J, Sarlis NJ, Litofsky D et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid16(12), 1229–1242 (2006).
   PubMed Web of Science ®Google Scholar
• Guidelines for the Management of Thyroid Cancer (Second Edition). Royal College of Physicians/British Thyroid Association, London, UK (2007).
   Google Scholar
• Luster M, Clarke SE, Dietlein M et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging35(10), 1941–1959 (2008).
   PubMed Web of Science ®Google Scholar
• Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid19(11), 1167–1214 (2009).
   PubMed Web of Science ®Google Scholar
• AJCC Cancer Staging Handbook (7th Edition). Springer, NY, USA (2010).
   Google Scholar
• Loevner LA, Kaplan SL, Cunnane ME, Moonis G. Cross-sectional imaging of the thyroid gland. Neuroimaging Clin. N. Am.18(3), 445–461, vii (2008).
   PubMedGoogle Scholar
• Moon WJ, Jung SL, Lee JH et al. Benign and malignant thyroid nodules: US differentiation – multicenter retrospective study. Radiology247(3), 762–770 (2008).
   PubMed Web of Science ®Google Scholar
• Frates MC, Benson CB, Charboneau JW et al. Management of thyroid nodules detected at US Society of Radiologists in Ultrasound consensus conference statement. Radiology237(3), 794–800 (2005).
   PubMed Web of Science ®Google Scholar
• Wong KT, Ahuja AT. Ultrasound of thyroid cancer. Cancer Imaging5, 157–166 (2005).
   PubMedGoogle Scholar
• Kim MJ, Kim EK, Park SI et al. US-guided fine-needle aspiration of thyroid nodules: indications, techniques, results. Radiographics28(7), 1869–1886; discussion 1887 (2008).
   PubMed Web of Science ®Google Scholar
• Rago T, Santini F, Scutari M, Pinchera A, Vitti P. Elastography: new developments in ultrasound for predicting malignancy in thyroid nodules. J. Clin. Endocrinol. Metab.92(8), 2917–2922 (2007).
   PubMed Web of Science ®Google Scholar
• Hong Y, Liu X, Li Z et al. Real-time ultrasound elastography in the differential diagnosis of benign and malignant thyroid nodules. J. Ultrasound Med.28(7), 861–867 (2009).
   PubMed Web of Science ®Google Scholar
• Rago T, Scutari M, Santini F et al. Real-time elastosonography: useful tool for refining the presurgical diagnosis in thyroid nodules with indeterminate or nondiagnostic cytology. J. Clin. Endocrinol. Metab.95(12), 5274–5280 (2010).
   PubMedGoogle Scholar
• Mansi L, Moncayo R, Cuccurullo V, Dottorini ME, Rambaldi PF. Nuclear medicine in diagnosis, staging and follow-up of thyroid cancer. Q. J. Nucl. Med. Mol. Imaging48(2), 82–95 (2004).
   PubMedGoogle Scholar
• Sebastianes FM, Cerci JJ, Soares Junior J et al. [Preoperative evaluation of cytologically indeterminate thyroid nodules with 18F-FDG PET]. Arq. Bras. Endocrinol. Metabol.52(7), 1176–1183 (2008).
   PubMedGoogle Scholar
• Hales NW, Krempl GA, Medina JE. Is there a role for fluorodeoxyglucose positron emission tomography/computed tomography in cytologically indeterminate thyroid nodules? Am. J. Otolaryngol.29(2), 113–118 (2008).
   PubMedGoogle Scholar
• Traugott AL, Dehdashti F, Trinkaus K et al. Exclusion of malignancy in thyroid nodules with indeterminate fine-needle aspiration cytology after negative 18F-fluorodeoxyglucose positron emission tomography: interim analysis. World J. Surg.34(6), 1247–1253 (2010).
   PubMed Web of Science ®Google Scholar
• Kouvaraki MA, Shapiro SE, Fornage BD et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery134(6), 946–954; discussion 954–945 (2003).
   PubMed Web of Science ®Google Scholar
• Kwak JY, Kim EK, Youk JH et al. Extrathyroid extension of well-differentiated papillary thyroid microcarcinoma on US. Thyroid18(6), 609–614 (2008).
   PubMedGoogle Scholar
• Park JS, Son KR, Na DG, Kim E, Kim S. Performance of preoperative sonographic staging of papillary thyroid carcinoma based on the sixth edition of the AJCC/UICC TNM classification system. AJR Am. J. Roentgenol.192(1), 66–72 (2009).
   PubMed Web of Science ®Google Scholar
• King AD, Ahuja AT, To EW, Tse GM, Metreweli C. Staging papillary carcinoma of the thyroid: magnetic resonance imaging vs ultrasound of the neck. Clin. Radiol.55(3), 222–226 (2000).
   PubMedGoogle Scholar
• Seo YL, Yoon DY, Lim KJ et al. Locally advanced thyroid cancer: can CT help in prediction of extrathyroidal invasion to adjacent structures? Am. J. Roentgenol.195(3), W240–W244 (2010).
   PubMed Web of Science ®Google Scholar
• Wang JC, Takashima S, Takayama F et al. Tracheal invasion by thyroid carcinoma: prediction using MR imaging. AJR Am. J. Roentgenol.177(4), 929–936 (2001).
   PubMedGoogle Scholar
• Wang J, Takashima S, Matsushita T et al. Esophageal invasion by thyroid carcinomas: prediction using magnetic resonance imaging. J. Comput. Assist. Tomogr.27(1), 18–25 (2003).
   PubMedGoogle Scholar
• Takashima S, Takayama F, Wang J, Kobayashi S, Kadoya M. Using MR imaging to predict invasion of the recurrent laryngeal nerve by thyroid carcinoma. AJR Am. J. Roentgenol.180(3), 837–842 (2003).
   PubMedGoogle Scholar
• Spanu A, Solinas ME, Chessa F, Sanna D, Nuvoli S, Madeddu G. 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging. J. Nucl. Med.50(2), 184–190 (2009).
   PubMedGoogle Scholar
• Wong KK, Zarzhevsky N, Cahill JM, Frey KA, Avram AM. Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma. AJR Am. J. Roentgenol.191(6), 1785–1794 (2008).
   PubMedGoogle Scholar
• Wong KK, Sisson JC, Koral KF, Frey KA, Avram AM. Staging of differentiated thyroid carcinoma using diagnostic 131I SPECT/CT. AJR Am. J. Roentgenol.195(3), 730–736 (2010).
   PubMedGoogle Scholar
• Ronga G, Fiorentino A, Paserio E et al. Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma? J. Nucl. Med.31(11), 1766–1771 (1990).
   PubMedGoogle Scholar
• Ozata M, Suzuki S, Miyamoto T et al. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J. Clin. Endocrinol. Metab.79(1), 98–105 (1994).
   PubMed Web of Science ®Google Scholar
• Buscombe JR. Radionuclides in the management of thyroid cancer. Cancer Imaging7, 202–209 (2007).
   PubMedGoogle Scholar
• Spencer CA, Takeuchi M, Kazarosyan M et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab.83(4), 1121–1127 (1998).
   PubMed Web of Science ®Google Scholar
• Tang YD, Kuzman JA, Said S et al. Low thyroid function leads to cardiac atrophy with chamber dilatation, impaired myocardial blood flow, loss of arterioles, and severe systolic dysfunction. Circulation112(20), 3122–3130 (2005).
   PubMed Web of Science ®Google Scholar
• Lind P, Kohlfurst S. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin. Nucl. Med.36(3), 194–205 (2006).
   PubMed Web of Science ®Google Scholar
• Wong KT, Choi FP, Lee YY, Ahuja AT. Current role of radionuclide imaging in differentiated thyroid cancer. Cancer Imaging8, 159–162 (2008).
   PubMedGoogle Scholar
• Fatourechi V, Hay ID, Mullan BP et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid10(7), 573–577 (2000).
   PubMedGoogle Scholar
• Reynolds JC. Percent 131I uptake and post-therapy 131I scans: their role in the management of thyroid cancer. Thyroid7(2), 281–284 (1997).
   PubMedGoogle Scholar
• Pace L, Klain M, Albanese C et al. Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment. Eur. J. Nucl. Med. Mol. Imaging33(2), 179–183 (2006).
   PubMedGoogle Scholar
• Franceschi M, Kusic Z, Franceschi D, Lukinac L, Roncevic S. Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma. J. Nucl. Med.37(3), 446–451 (1996).
   PubMedGoogle Scholar
• Filesi M, Signore A, Ventroni G, Melacrinis FF, Ronga G. Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases. J. Nucl. Med.39(9), 1542–1546 (1998).
   PubMedGoogle Scholar
• Norden MM, Larsson F, Tedelind S et al. Down-regulation of the sodium/iodide symporter explains 131I-induced thyroid stunning. Cancer Res.67(15), 7512–7517 (2007).
   PubMed Web of Science ®Google Scholar
• Morris LF, Waxman AD, Braunstein GD. Thyroid stunning. Thyroid13(4), 333–340 (2003).
   PubMed Web of Science ®Google Scholar
• Muratet JP, Daver A, Minier JF, Larra F. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J. Nucl. Med.39(9), 1546–1550 (1998).
   PubMedGoogle Scholar
• Morris LF, Waxman AD, Braunstein GD. The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. J. Clin. Endocrinol. Metab.86(8), 3507–3511 (2001).
   PubMedGoogle Scholar
• Silberstein EB. Comparison of outcomes after 123I versus 131I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J. Nucl. Med.48(7), 1043–1046 (2007).
   PubMed Web of Science ®Google Scholar
• Intenzo CM, Jabbour S, Dam HQ, Capuzzi DM. Changing concepts in the management of differentiated thyroid cancer. Semin. Nucl. Med.35(4), 257–265 (2005).
   PubMedGoogle Scholar
• Hilditch TE, Dempsey MF, Bolster AA, McMenemin RM, Reed NS. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. Eur. J. Nucl. Med. Mol. Imaging29(6), 783–788 (2002).
   PubMedGoogle Scholar
• Urhan M, Dadparvar S, Mavi A et al. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement. Eur. J. Nucl. Med. Mol. Imaging34(7), 1012–1017 (2007).
   PubMed Web of Science ®Google Scholar
• Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J. Clin. Endocrinol. Metab.85(1), 175–178 (2000).
   PubMed Web of Science ®Google Scholar
• Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J. Clin. Endocrinol. Metab.87(4), 1499–1501 (2002).
   PubMed Web of Science ®Google Scholar
• Baudin E, Do Cao C, Cailleux AF et al. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J. Clin. Endocrinol. Metab.88(3), 1107–1111 (2003).
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J. Clin. Endocrinol. Metab.87(4), 1490–1498 (2002).
   PubMed Web of Science ®Google Scholar
• Ma C, Xie J, Kuang A. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results? J. Nucl. Med.46(7), 1164–1170 (2005).
   PubMedGoogle Scholar
• Ma C, Kuang A, Xie J, Ma T. Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning. J. Nucl. Med.46(9), 1473–1480 (2005).
   PubMedGoogle Scholar
• Mazzaferri EL, Robbins RJ, Spencer CA et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J. Clin. Endocrinol. Metab.88(4), 1433–1441 (2003).
   PubMed Web of Science ®Google Scholar
• Fatourechi V, Hay ID. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Semin. Nucl. Med.30(2), 107–114 (2000).
   PubMedGoogle Scholar
• Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J. Clin. Endocrinol. Metab.87(7), 3242–3247 (2002).
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Berg G, Cohen O et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur. J. Endocrinol.150(2), 105–112 (2004).
   PubMed Web of Science ®Google Scholar
• Wong KK, Zarzhevsky N, Cahill JM, Frey KA, Avram AM. Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma. Br. J. Radiol.82(982), 860–876 (2009).
   PubMedGoogle Scholar
• Feine U. Fluor-18-deoxyglucose positron emission tomography in differentiated thyroid cancer. Eur. J. Endocrinol.138(5), 492–496 (1998).
   PubMedGoogle Scholar
• Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J. Nucl. Med.42(1), 71–76 (2001).
   PubMedGoogle Scholar
• Nahas Z, Goldenberg D, Fakhry C et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope115(2), 237–243 (2005).
   PubMed Web of Science ®Google Scholar
• Robbins RJ, Wan Q, Grewal RK et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J. Clin. Endocrinol. Metab.91(2), 498–505 (2006).
   PubMed Web of Science ®Google Scholar
• Grunwald F, Kalicke T, Feine U et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J. Nucl. Med.26(12), 1547–1552 (1999).
   PubMedGoogle Scholar
• Feine U, Lietzenmayer R, Hanke JP et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J. Nucl. Med.37(9), 1468–1472 (1996).
   PubMed Web of Science ®Google Scholar
• Altenvoerde G, Lerch H, Kuwert T et al. Positron emission tomography with 18F-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels and negative iodine scans. Langenbecks Arch. Surg.383, 160–163 (1998).
   PubMedGoogle Scholar
• Moog F, Linke R, Manthey N et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J. Nucl. Med.41(12), 1989–1995 (2000).
   PubMedGoogle Scholar
• Petrich T, Borner AR, Weckesser E et al. Follow-up of differentiated thyroid cancer patients using rhTSH – preliminary results. Nuklearmedizin40(1), 7–14 (2001).
   PubMedGoogle Scholar
• Buck AK, Nekolla S, Ziegler S et al. SPECT/CT. J. Nucl. Med.49(8), 1305–1319 (2008).
   PubMed Web of Science ®Google Scholar
• Shapiro B, Rufini V, Jarwan A et al. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131I scans in patients with thyroid cancer. Semin. Nucl. Med.30(2), 115–132 (2000).
   PubMed Web of Science ®Google Scholar
• Hasegawa BH, Iwata K, Wong KH et al. Dual-modality imaging of function and physiology. Acad. Radiol.9(11), 1305–1321 (2002).
   PubMed Web of Science ®Google Scholar
• Chowdhury FU, Scarsbrook AF. The role of hybrid SPECT-CT in oncology: current and emerging clinical applications. Clin. Radiol.63(3), 241–251 (2008).
   PubMedGoogle Scholar
• Patton JA, Delbeke D, Sandler MP. Image fusion using an integrated, dual-head coincidence camera with X-ray tube-based attenuation maps. J. Nucl. Med.41(8), 1364–1368 (2000).
   PubMedGoogle Scholar
• Ingui CJ, Shah NP, Oates ME. Endocrine neoplasm scintigraphy: added value of fusing SPECT/CT images compared with traditional side-by-side analysis. Clin. Nucl. Med.31(11), 665–672 (2006).
   PubMedGoogle Scholar
• von Schulthess GK, Pelc NJ. Integrated-modality imaging: the best of both worlds. Acad. Radiol.9(11), 1241–1244 (2002).
   PubMedGoogle Scholar
• Yamamoto Y, Nishiyama Y, Monden T, Matsumura Y, Satoh K, Ohkawa M. Clinical usefulness of fusion of 131I SPECT and CT images in patients with differentiated thyroid carcinoma. J. Nucl. Med.44(12), 1905–1910 (2003).
   PubMedGoogle Scholar
• Schillaci O. Hybrid SPECT/CT. a new era for SPECT imaging? Eur. J. Nucl. Med. Mol. Imaging32(5), 521–524 (2005).
   PubMed Web of Science ®Google Scholar
• Ruf J, Lehmkuhl L, Bertram H et al. Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma. Nucl. Med. Commun.25(12), 1177–1182 (2004).
   PubMedGoogle Scholar
• Schmidt D, Szikszai A, Linke R, Bautz W, Kuwert T. Impact of 131I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation. J. Nucl. Med.50(1), 18–23 (2009).
   PubMedGoogle Scholar
• Wang H, Fu HL, Li JN, Zou RJ, Gu ZH, Wu JC. The role of single-photon emission computed tomography/computed tomography for precise localization of metastases in patients with differentiated thyroid cancer. Clin. Imaging33(1), 49–54 (2009).
   PubMedGoogle Scholar
• Aide N, Heutte N, Rame JP et al. Clinical relevance of single-photon emission computed tomography/computed tomography of the neck and thorax in postablation 131I scintigraphy for thyroid cancer. J. Clin. Endocrinol. Metab.94(6), 2075–2084 (2009).
   PubMedGoogle Scholar
• Mustafa M, Kuwert T, Weber K et al. Regional lymph node involvement in T1 papillary thyroid carcinoma: a bicentric prospective SPECT/CT study. Eur. J. Nucl. Med. Mol. Imaging37(8), 1462–1466 (2010).
   PubMedGoogle Scholar
• Grewal RK, Tuttle RM, Fox J et al. The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer. J. Nucl. Med.51(9), 1361–1367 (2010).
   PubMedGoogle Scholar
• Tharp K, Israel O, Hausmann J et al. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging31(10), 1435–1442 (2004).
   PubMedGoogle Scholar
• Chen L, Luo Q, Shen Y et al. Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma. J. Nucl. Med.49(12), 1952–1957 (2008).
   PubMedGoogle Scholar
• Kohlfuerst S, Igerc I, Lobnig M et al. Posttherapeutic 131I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen. Eur. J. Nucl. Med. Mol. Imaging36(6), 886–893 (2009).
   PubMedGoogle Scholar
• Barwick T, Murray I, Megadmi H et al. Single photon emission computed tomography (SPECT)/computed tomography using iodine-123 in patients with differentiated thyroid cancer: additional value over whole body planar imaging and SPECT. Eur. J. Endocrinol.162(6), 1131–1139 (2010).
   PubMedGoogle Scholar
• Schmidt D, Linke R, Uder M, Kuwert T. Five months’ follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by 131I-SPECT/CT at the first radioablation. Eur. J. Nucl. Med. Mol. Imaging37(4), 699–705 (2010).
   PubMedGoogle Scholar
• Bockisch A, Freudenberg LS, Schmidt D, Kuwert T. Hybrid imaging by SPECT/CT and PET/CT: proven outcomes in cancer imaging. Semin. Nucl. Med.39(4), 276–289 (2009).
   PubMed Web of Science ®Google Scholar
• Dong MJ, Liu ZF, Zhao K et al. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis. Nucl. Med. Commun.30(8), 639–650 (2009).
   PubMedGoogle Scholar
• Razfar A, Branstetter BFT, Christopoulos A et al. Clinical usefulness of positron emission tomography–computed tomography in recurrent thyroid carcinoma. Arch. Otolaryngol. Head Neck Surg.136(2), 120–125 (2010).
   PubMedGoogle Scholar
• Shammas A, Degirmenci B, Mountz JM et al.18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J. Nucl. Med.48(2), 221–226 (2007).
   PubMedGoogle Scholar
• Palmedo H, Bucerius J, Joe A et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J. Nucl. Med.47(4), 616–624 (2006).
   PubMedGoogle Scholar
• Phan HT, Jager PL, Paans AM et al. The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging35(5), 958–965 (2008).
   PubMedGoogle Scholar
• Freudenberg LS, Antoch G, Frilling A et al. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET. Eur. J. Nucl. Med. Mol. Imaging35(5), 950–957 (2008).
   PubMedGoogle Scholar
• Tuttle RM, Leboeuf R, Martorella AJ. Papillary thyroid cancer: monitoring and therapy. Endocrinol. Metab. Clin. North Am.36(3), 753–778, vii (2007).
   PubMedGoogle Scholar
• Gupta-Abramson V, Troxel AB, Nellore A et al. Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol.26(29), 4714–4719 (2008).
   PubMed Web of Science ®Google Scholar
• Brans B, Bodei L, Giammarile F et al. Clinical radionuclide therapy dosimetry: the quest for the ‘Holy Gray’. Eur. J. Nucl. Med. Mol. Imaging34(5), 772–786 (2007).
   PubMedGoogle Scholar
• Prideaux AR, Song H, Hobbs RF et al. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J. Nucl. Med.48(6), 1008–1016 (2007).
   PubMedGoogle Scholar
• Jentzen W, Hobbs RF, Stahl A, Knust J, Sgouros G, Bockisch A. Pre-therapeutic 124I PET(/CT) dosimetry confirms low average absorbed doses per administered 131I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging37(5), 884–895 (2010).
   PubMedGoogle Scholar
• Jentzen W, Freudenberg L, Eising EG, Sonnenschein W, Knust J, Bockisch A. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J. Nucl. Med.49(6), 1017–1023 (2008).
   PubMedGoogle Scholar